Impact of ixekizumab on skin pain in patients with moderate to severe psoriasis compared to placebo and etanercept in UNCOVER-2 - 21/04/16
Alice Gottlieb, MD, Tufts University School of Medicine, Boston, MA, United States; Thomas Luger, MD, Department of Dermatology, Munster, Germany; Luis Puig Sanz, MD, PhD, Universitat Autonoma de Barcelona Medical School, Barcelona, Spain; Nikai Enkeleida, MBA, MS, Eli Lilly and Company, Indianapolis, IN, United States; Baojin Zhu, PhD, Eli Lilly and Company, Indianapolis, IN, United States; Emily Edson-Heredia, MS, Eli Lilly and Company, Indianapolis, IN, United States; Hilde Carlier, MD, Eli Lilly and Company, Indianapolis, IN, United States; Chen-Yen Lin, PhD, Eli Lilly and Company, Indianapolis, IN, United States; Alison Potts Bleakman, PhD, Eli Lilly and Company, Indianapolis, IN, United States; Orin Goldblum, MD, Eli Lilly and Company, Indianapolis, IN, United States
Le texte complet de cet article est disponible en PDF.| Supported by Eli Lilly & Company. |
Vol 74 - N° 5S1
P. AB57 - mai 2016 Retour au numéro
Article précédent
- Hypertrophic osteoarthropathy: A case report
- Impact of lichen sclerosus, lichen planus, and vulvodynia on quality of life for patients using the vulvar-specific Skindex-29 patient reported outcome measure
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?